SEC Form 4 · accession 0001179110-18-002766
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurie Stelzer
Officer — SVP, Chief Financial Officer
Period of report
Feb 22, 2018
Accepted (ET)
Feb 23, 2018 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2018 | M | 11,392 | $0.00 | A | 51,449 | D | |
| Common StockF1 | Feb 22, 2018 | F | 3,939 | $19.28 | D | 47,510 | D | |
| Common StockF2 | holding | — | — | — | 10,000 | I | By trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Feb 22, 2018 | M | 11,392 | D | — | — | Common Stock | 11,392 | 34,176 | D |
Explanation of responses
- F1The reported disposition of 3,939 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
- F2The reporting person is co-trustee of the Gregory and Laureen Stelzer Living Trust.
- F3This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.